Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) is associated with low hypoglycemia risk (7) due to enhancement of insulin secretion that is glucose-dependent (8) and preserved glucagon response to hypoglycemia (9, 10). This evidence concerns the gene GCG and Hypoglycemia.